RecruitingNCT07696871
CBD oil versus placebo for treatment-resistant depression
About this title
Read the official source — NCT07696871Medication studyAges 18–69Brazil
Understand this study
Who could participate?
Listed age limits: 18 years to 69 years.
- Listed locations
- TubarãoSee all locations and recruitment
- Study phase
- Phase 1 / Phase 2This study spans more than one phase, so it may combine goals such as safety, dosing, and early effectiveness.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: June 1, 2026
- Recruitment status
- Recruiting
- Enrollment listed in the registry
- 120
- Sponsor
- Universidade do Sul de Santa Catarina
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 1 / Phase 2This study spans more than one phase, so it may combine goals such as safety, dosing, and early effectiveness.
- Locations
- Brazil
- Age range
- From 18 Years to 69 Years
- Official registry ID
- NCT07696871
- Official title
Show the full official title
Effects of Full-Spectrum Cannabidiol Oil on Symptoms of Treatment-Resistant Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Trial
Recruitment & locations
Currently recruitingA study may be recruiting, but some locations may no longer be accepting participants. Confirm availability with the research team.
Tubarão
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Universidade do Sul de Santa Catarina.
Does this study involve medication?
Yes. The study involves medication, including Full-spectrum CBD oil 100 mg/mL and Placebo oil (MCT oil).
Who can participate?
Listed age limits: 18 years to 69 years.
Is this study still recruiting?
The registry lists this study as recruiting.
